CA3199736A1 - Formulations and methods for treating conditions of the eye - Google Patents

Formulations and methods for treating conditions of the eye

Info

Publication number
CA3199736A1
CA3199736A1 CA3199736A CA3199736A CA3199736A1 CA 3199736 A1 CA3199736 A1 CA 3199736A1 CA 3199736 A CA3199736 A CA 3199736A CA 3199736 A CA3199736 A CA 3199736A CA 3199736 A1 CA3199736 A1 CA 3199736A1
Authority
CA
Canada
Prior art keywords
pharmaceutical formulation
administered
azithromycin
sub
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3199736A
Other languages
English (en)
French (fr)
Inventor
Paul Badawi
David Y. Badawi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sight Sciences Inc
Original Assignee
Sight Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sight Sciences Inc filed Critical Sight Sciences Inc
Publication of CA3199736A1 publication Critical patent/CA3199736A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3199736A 2020-11-23 2021-11-23 Formulations and methods for treating conditions of the eye Pending CA3199736A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063117393P 2020-11-23 2020-11-23
US63/117,393 2020-11-23
US202163254958P 2021-10-12 2021-10-12
US63/254,958 2021-10-12
PCT/US2021/060653 WO2022109497A1 (en) 2020-11-23 2021-11-23 Formulations and methods for treating conditions of the eye

Publications (1)

Publication Number Publication Date
CA3199736A1 true CA3199736A1 (en) 2022-05-27

Family

ID=81658809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3199736A Pending CA3199736A1 (en) 2020-11-23 2021-11-23 Formulations and methods for treating conditions of the eye

Country Status (6)

Country Link
US (5) US20220160668A1 (cg-RX-API-DMAC10.html)
EP (1) EP4247367A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023550632A (cg-RX-API-DMAC10.html)
AU (1) AU2021381495A1 (cg-RX-API-DMAC10.html)
CA (1) CA3199736A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022109497A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095412B2 (en) 2012-03-20 2015-08-04 Sight Sciences, Inc. Ocular delivery systems and methods
US10299958B2 (en) 2015-03-31 2019-05-28 Sight Sciences, Inc. Ocular delivery systems and methods
US11504270B1 (en) 2019-09-27 2022-11-22 Sight Sciences, Inc. Ocular delivery systems and methods
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US11877954B2 (en) 2022-03-16 2024-01-23 Sight Sciences, Inc. Devices and methods for intraocular tissue manipulation
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614545A (en) 1988-06-09 1997-03-25 Leonard Bloom Topical composition for treatment of blepharitis
US4957918A (en) 1988-06-09 1990-09-18 Leonard Bloom Topical treatment of blepharitis
AT393454B (de) 1989-10-04 1991-10-25 Ido Dr Egerer Augentropfenzusatz
US6107289A (en) 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
RU2004118424A (ru) 2001-11-19 2005-05-10 Новартис АГ (CH) Применение аскомицина для лечения блефарита
AR042890A1 (es) 2003-01-16 2005-07-06 Sucampo Pharmaceuticals Inc Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
KR20050092429A (ko) 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
CA2597525A1 (en) 2005-02-17 2006-08-24 Senju Pharmaceutical Co., Ltd. Solid ophthalmic drug for external use
US20070004672A1 (en) 2005-07-01 2007-01-04 Dharmendra Jani Long lasting alginate dry eye, related methods of manufacture and methods of use
FR2891460B1 (fr) 2005-09-30 2010-07-30 Galderma Sa Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
EP1964575B1 (en) 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
US20090318422A1 (en) 2006-08-28 2009-12-24 Akiharu Isowaki Ophthalmic percutaneous absorption type preparation
US20080057022A1 (en) 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
US7659259B2 (en) 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
US20080312194A1 (en) 2007-02-28 2008-12-18 Ousler Iii George W Methods and compositions for normalizing meibomian gland secretions
CA2685230C (en) * 2007-05-04 2012-10-16 Bausch & Lomb Incorporated Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
WO2008137826A2 (en) 2007-05-07 2008-11-13 Bausch & Lomb Incorporated Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
US20110059925A1 (en) 2008-03-26 2011-03-10 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
MX2011000247A (es) * 2008-07-10 2011-03-30 Inspire Pharmaceuticals Inc Composicion farmaceutica para el tratamiento de blefaritis.
WO2010085572A1 (en) 2009-01-23 2010-07-29 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with azithromycin
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
ES2752008T3 (es) 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
WO2011068786A2 (en) 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
US9011861B2 (en) * 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
AU2011287544B2 (en) 2010-08-06 2014-12-11 Galderma Research & Development Combination of compounds for treating or preventing skin diseases
WO2012092375A1 (en) 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating dry eye
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
WO2013003731A2 (en) 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
CA2848397C (en) * 2011-09-14 2022-04-26 Forsight Vision5, Inc. Ocular insert apparatus and methods
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
CA2886042C (en) 2012-09-28 2015-11-24 Santen Pharmaceutical Co., Ltd. Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage
US9044508B2 (en) 2013-03-15 2015-06-02 Insite Vision Corporation Concentrated aqueous azalide formulations
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9931306B2 (en) * 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye
US9597328B2 (en) * 2015-02-24 2017-03-21 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
US9393243B1 (en) 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
WO2017055924A2 (en) 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
FR3041540B1 (fr) 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante a rincer, contenant de l'ivermectine.
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
GB201522144D0 (en) 2015-12-15 2016-01-27 Univ Manchester Compositions and uses and methods relating thereto
US9439917B1 (en) 2015-12-28 2016-09-13 Shetal Amit Shah Anti-blepharitis compositions and their use
EA201891743A1 (ru) 2016-02-04 2019-01-31 Гордон Уэйн Дайер Способ нарушения состояния касси-бакстера
US11260035B2 (en) 2016-10-12 2022-03-01 Ps Therapies Ltd Topical compositions and methods of use thereof
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
GB201706969D0 (en) 2017-05-02 2017-06-14 Medherant Ltd Formulation
US20190008920A1 (en) * 2017-05-19 2019-01-10 Ocugen, Inc. Ophthalmic compositions and methods of use
EP3644966A4 (en) 2017-06-29 2021-03-24 Advaite LLC TREATMENT AND DIAGNOSIS OF EYE SURFACE DISORDERS
CA3080166A1 (en) 2017-11-21 2019-05-31 Axerovision, Inc. Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
WO2019113475A1 (en) 2017-12-07 2019-06-13 Dermavant Sciences GmbH Topical ointment formulations and their use in treating skin conditions
WO2020077284A1 (en) 2018-10-12 2020-04-16 Hovione Scientia Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites
US12161752B2 (en) * 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
US20210052493A1 (en) 2019-08-21 2021-02-25 Joseph Sinclair Non-aqueous anti-parasitic ointment for ophthalmological use
WO2021067823A2 (en) 2019-10-05 2021-04-08 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
WO2021087051A1 (en) 2019-10-30 2021-05-06 Ps Therapy Ltd. Topical compositions and methods of use thereof
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
US11872213B2 (en) 2021-01-28 2024-01-16 Glaukos Corporation Formulations

Also Published As

Publication number Publication date
WO2022109497A1 (en) 2022-05-27
US20220160668A1 (en) 2022-05-26
US11419886B2 (en) 2022-08-23
EP4247367A1 (en) 2023-09-27
US11554134B2 (en) 2023-01-17
US20220354878A1 (en) 2022-11-10
JP2023550632A (ja) 2023-12-04
US20240415860A1 (en) 2024-12-19
AU2021381495A1 (en) 2023-06-22
EP4247367A4 (en) 2024-10-16
US20230210878A1 (en) 2023-07-06
US20220160743A1 (en) 2022-05-26
US11925657B2 (en) 2024-03-12

Similar Documents

Publication Publication Date Title
CN112135603B (zh) 包含奈必洛尔的药物组合物
EP3139914B1 (en) Compounds for treating ophthalmic diseases and disorders
EP4247367A1 (en) Formulations and methods for treating conditions of the eye
ES3040229T3 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CN119656170A (zh) 使用尼达尼布来治疗具有异常新生血管形成的眼病的组合物和方法
IL290069B1 (en) Methods for treating eye conditions
US12454539B2 (en) Controlled-delivery cromakalim prodrugs
JP2023550632A5 (cg-RX-API-DMAC10.html)
JP2022525254A (ja) 眼科用医薬品製剤の調製におけるノトギンセノシド抽出物の使用
IL126836A (en) Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases
US10973758B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
CA3004587A1 (en) Use of proteasome inhibitors to treat ocular disorders
US20250213541A1 (en) Suspension compositions of multi-target inhibitors
Wang et al. A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension
RU2836815C1 (ru) Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования
HK40100601A (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
HK40044057B (en) Pharmaceutical compositions comprising nebivolol
TW202038928A (zh) 多目標抑製劑的懸浮液組合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241023

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241023

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428